Ranbaxy reportedly drops generic drug bid

India's Ranbaxy has reportedly dropped out of the bidding war for the generic drug business of Merck KGaA. The news immediately buoyed Ranbaxy's stock prices. Sources indicated that Ranbaxy, which had submitted a bid for the unit, determined that the valuation had gone too high to remain in pursuit. Some analysts have estimated that the sale price could should as high as $6.58 billion.

- read this AP report

Related Articles:
New bid rumors heat up Merck KGaA stock. Report
Bidding war heats up for Merck KGaA generic unit. Report
Merck KGaA shortens list of bidders for drug unit. Report
Ranbaxy touts R&D abilities in new discovery pact. Report

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.